A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Delta-like protein 3 (DLL3) is highly expressed in solid tumors, including neuroendocrine carcinomas/neuroendocrine tumors (NEC/NET). Rovalpituzumab tesirine (Rova-T) is a DLL3-targeting antibody-drug conjugate. Patients with NECs and other advanced DLL3-expressing tumors were enrolled in this phase I/II study (NCT02709889). The primary endpoint was safety. Two hundred patients were enrolled: 101 with NEC/NET (large-cell NEC, gastroenteropancreatic NEC, neuroendocrine prostate cancer, and other NEC/NET) and 99 with other solid tumors (melanoma, medullary thyroid cancer [MTC], glioblastoma, and other). The recommended phase II dose (RP2D) was 0.3 mg/kg every 6 weeks (q6w) for two cycles. At the RP2D, grade 3/4 adverse events included anemia (17%), thrombocytopenia (15%), and elevated aspartate aminotransferase (8%). Responses were confirmed in 15/145 patients (10%) treated at 0.3 mg/kg, including 9/69 patients (13%) with NEC/NET. Rova-T at 0.3 mg/kg q6w had manageable toxicity, with antitumor activity observed in patients with NEC/NET, melanoma, MTC, and glioblastoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 8×
“Nausea 5 (29) 0 3 (30) 0 4 (22) 1 (6) 12 (39) 2 (6) 29 (42) 2 (3) 53 (37) 5 (3)”
InfluentialOstrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994 · cited 5×
“Diarrhea 3 (18) 0 0 0 2 (11) 0 4 (13) 1 (3) 14 (20) 2 (3) 23 (16) 3 (2)”
InfluentialPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · cited 5×
“Diarrhea 3 (18) 0 0 0 2 (11) 0 4 (13) 1 (3) 14 (20) 2 (3) 23 (16) 3 (2)”
InfluentialWells, S. A., Asa, S. L., Dralle, H., Elisei, R., Evans, D. B., Gagel, R. F., Lee, N., Machens, A., Moley, J. F., Pacini, F., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0335 · Cited by 2,444 · cited 2×
“≥4 8 (40) 2 (15) 8 (35) 19 (44) 27 (27) 64 (32)”
Sorbye, H., Welin, S., Langer, S. W., Vestermark, L. W., Holt, N., Osterlund, P., Dueland, S., Hofsli, E., Guren, M. G., Ohrling, K., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds276 · Cited by 1,027
High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Stupp, R., Brada, M., van den Bent, M. J., Tonn, J.-C., & Pentheroudakis, G. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu050 · Cited by 772
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Dummer, R., Hauschild, A., Guggenheim, M., Keilholz, U., & Pentheroudakis, G. (2012) · Annals of Oncology · doi:10.1093/annonc/mds229 · Cited by 714
Saunders, L. R., Bankovich, A. J., Anderson, W. C., Aujay, M. A., Bheddah, S., Black, K., Desai, R., Escarpe, P. A., Hampl, J., Laysang, A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac9459 · Cited by 600 · cited 3×
“Photosensitivity reaction 5 (29) 0 5 (50) 0 5 (28) 0 6 (19) 0 16 (23) 3 (4) 37 (26) 3 (2)”
Rudin, C. M., Pietanza, M. C., Bauer, T. M., Ready, N., Morgensztern, D., Glisson, B. S., Byers, L. A., Johnson, M. L., Burris, H. A., Robert, F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30565-4 · Cited by 574
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin
Mitry, E., Baudin, E., Ducreux, M., Sabourin, J.-C., Rufié, P., Aparicio, T., Lasser, P., Elias, D., Duvillard, P., Schlumberger, M., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690325 · Cited by 496 · cited 6×
“Abdominal pain 2 (12) 0 2 (20) 1 (10) 2 (11) 0 6 (19) 1 (3) 18 (26) 3 (4) 30 (21) 5 (3)”
Influential
Cited by
Notch signaling pathway in cancer: from mechanistic insights to targeted therapies
Shi, Q., Xue, C., Zeng, Y., Yuan, X., Chu, Q., Jiang, S., Wang, J., Zhang, Y., Zhu, D., & Li, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01828-x · Cited by 401
Molecular events in neuroendocrine prostate cancer development
Wang, Y., Wang, Y., Ci, X., Choi, S. Y. C., Crea, F., Lin, D., & Wang, Y. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00490-0 · Cited by 182
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer
Rudin, C. M., Reck, M., Johnson, M. L., Blackhall, F., Hann, C. L., Yang, J. C.-H., Bailis, J. M., Bebb, G., Goldrick, A., Umejiego, J., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01464-y · Cited by 181
“A phase 1/2 study that evaluated Rova-T in 200 patients with DLL3expressing advanced tumors, including NECs and other NETs, revealed a consolidated ORR of 13% in patients with NEC/NET [109].”
MethodSelf-citationDLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms
Yao, J. C., Bergsland, E. K., Aggarwal, R. R., Aparicio, A. M., Beltran, H., Crabtree, J. S., Hann, C. L., Ibrahim, T., Byers, L. A., Sasano, H., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac161 · Cited by 108
Self-citationTargeting the DLL/Notch Signaling Pathway in Cancer: Challenges and Advances in Clinical Development
You, W., Schuetz, T. J., & Lee, S. H. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0243 · Cited by 84
Metadata
- Authors
- Mansfield, A. S., Hong, D. S., Hann, C. L., Farago, A. F., Beltran, H., Waqar, S. N., Hendifar, A. E., Anthony, L. B., Taylor, M. H., Bryce, A. H., Tagawa, S. T., Lewis, K., Niu, J., Chung, C. H., Cleary, J. M., Rossi, M., Ludwig, C., Valenzuela, R., Luo, Y., & Aggarwal, R.
- Affiliations
- Mayo Clinic (US)
- The University of Texas MD Anderson Cancer Center (US)
- Johns Hopkins University (US)
- Massachusetts General Hospital (US)
- Dana-Farber Cancer Institute (US)
- Washington University in St. Louis (US)
- Cedars-Sinai Medical Center (US)
- Albert B. Chandler Hospital (US)
- Providence Portland Medical Center (US)
- Mayo Clinic Hospital (US)
- Weill Cornell Medicine (US)
- University of Colorado Denver (US)
- Banner MD Anderson Cancer Center (US)
- Moffitt Cancer Center (US)
- AbbVie (United States) (US)
- University of California, San Francisco (US)
- Corresponding author
- Aggarwal, Rahul
- ORCID
- Venue
- npj Precision Oncology
- Published
- 2021-08-05
- Volume
- 5
- Issue
- 1
- Pages
- 74-74
- ISSN
- 2397-768X (ISSN-L)
- PMC
- PMC8342450
- OpenAlex
- W3189704246
- Cited by
- 80
- References
- 32
- Citations by year
- 2026: 15 · 2025: 21 · 2024: 12 · 2023: 17 · 2022: 10 · 2021: 5
- FWCI
- 7.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- npj Precision Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- AbbVie
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- rovalpituzumab tesirine, DLL3, antibody-drug conjugates, neuroendocrine carcinoma, neuroendocrine tumors, advanced solid tumors, melanoma, medullary thyroid carcinoma, glioblastoma, recommended phase 2 dose, anticancer activity, adverse events, anemia, thrombocytopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors. https://app.cochat.ai/papers/10.1038/s41698-021-00214-y
- The paper
- Mansfield, A. S., Hong, D. S., Hann, C. L., Farago, A. F., Beltran, H., Waqar, S. N., Hendifar, A. E., Anthony, L. B., Taylor, M. H., Bryce, A. H., Tagawa, S. T., Lewis, K., Niu, J., Chung, C. H., Cleary, J. M., Rossi, M., Ludwig, C., Valenzuela, R., Luo, Y., & Aggarwal, R. (2021). A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors. npj Precision Oncology. https://doi.org/10.1038/s41698-021-00214-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.